Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCTY1102 in Advanced Solid Tumors with KRAS/NRAS G12D Mutation and HLA-A*11:01
NCT07014878Phase 1Not yet recruiting
- Sponsor
- Dingchi Biotech
- Start
- May 2026
- Primary completion
- Aug 2028
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DCTY1102 in colorectal cancer (CRC), lung cancer and pancreatic cancer (PC), sponsored by Dingchi Biotech. Primary endpoints: Dose Limiting Toxicity at 28 days, Maximum Tolerated Dose at 28 days and 2 more. Planned start May 2026; status: not yet recruiting.
02
Drugs
DCTY1102
03
Conditions
colorectal cancer (CRC)lung cancerpancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07014878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07014878.